Header Logo

Connection

ANN LEEN to Female

Back to Details
This is a "connection" page, showing publications ANN LEEN has written about Female.
ANN LEEN
Connection Strength
0.275
Female
  1. Clinical effects of administering leukemia-specific donor T cells to patients with AML/MDS after allogeneic transplant. Blood. 2021 05 13; 137(19):2585-2597.
    View in: PubMed
    Score: 0.029
  2. Dynamics of virus-specific T cell immunity in pediatric liver transplant recipients. Am J Transplant. 2018 09; 18(9):2238-2249.
    View in: PubMed
    Score: 0.024
  3. Immunologic Profiling of Human Metapneumovirus for the Development of Targeted Immunotherapy. J Infect Dis. 2017 09 15; 216(6):678-687.
    View in: PubMed
    Score: 0.022
  4. Characterizing the Cellular Immune Response to Parainfluenza Virus 3. J Infect Dis. 2017 07 15; 216(2):153-161.
    View in: PubMed
    Score: 0.022
  5. Activity of broad-spectrum T cells as treatment for AdV, EBV, CMV, BKV, and HHV6 infections after HSCT. Sci Transl Med. 2014 Jun 25; 6(242):242ra83.
    View in: PubMed
    Score: 0.018
  6. Safety and clinical efficacy of rapidly-generated trivirus-directed T cells as treatment for adenovirus, EBV, and CMV infections after allogeneic hematopoietic stem cell transplant. Mol Ther. 2013 Nov; 21(11):2113-21.
    View in: PubMed
    Score: 0.017
  7. Multicenter study of banked third-party virus-specific T cells to treat severe viral infections after hematopoietic stem cell transplantation. Blood. 2013 Jun 27; 121(26):5113-23.
    View in: PubMed
    Score: 0.016
  8. Cytotoxic T lymphocyte therapy with donor T cells prevents and treats adenovirus and Epstein-Barr virus infections after haploidentical and matched unrelated stem cell transplantation. Blood. 2009 Nov 05; 114(19):4283-92.
    View in: PubMed
    Score: 0.013
  9. Monoculture-derived T lymphocytes specific for multiple viruses expand and produce clinically relevant effects in immunocompromised individuals. Nat Med. 2006 Oct; 12(10):1160-6.
    View in: PubMed
    Score: 0.010
  10. Adenoviral infections in hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2006 Mar; 12(3):243-51.
    View in: PubMed
    Score: 0.010
  11. Final outcomes from a phase 2 trial of posoleucel in allogeneic hematopoietic cell transplant recipients. Blood Adv. 2024 09 10; 8(17):4740-4750.
    View in: PubMed
    Score: 0.009
  12. LOAd703, an oncolytic virus-based immunostimulatory gene therapy, combined with chemotherapy for unresectable or metastatic pancreatic cancer (LOKON001): results from arm 1 of a non-randomised, single-centre, phase 1/2 study. Lancet Oncol. 2024 Apr; 25(4):488-500.
    View in: PubMed
    Score: 0.009
  13. Incongruity between T cell receptor recognition of breast cancer hotspot mutations ESR1 Y537S and D538G following exogenous peptide loading versus endogenous antigen processing. Cytotherapy. 2024 03; 26(3):266-275.
    View in: PubMed
    Score: 0.009
  14. Selectively targeting myeloid-derived suppressor cells through TRAIL receptor 2 to enhance the efficacy of CAR T cell therapy for treatment of breast cancer. J Immunother Cancer. 2021 11; 9(11).
    View in: PubMed
    Score: 0.007
  15. T-Cell Therapy for Lymphoma Using Nonengineered Multiantigen-Targeted T Cells Is Safe and Produces Durable Clinical Effects. J Clin Oncol. 2021 05 01; 39(13):1415-1425.
    View in: PubMed
    Score: 0.007
  16. CAR T cell therapy for breast cancer: harnessing the tumor milieu to drive T cell activation. J Immunother Cancer. 2018 05 10; 6(1):34.
    View in: PubMed
    Score: 0.006
  17. Asian Elephant T Cell Responses to Elephant Endotheliotropic Herpesvirus. J Virol. 2018 03 15; 92(6).
    View in: PubMed
    Score: 0.006
  18. Off-the-Shelf Virus-Specific T Cells to Treat BK Virus, Human Herpesvirus 6, Cytomegalovirus, Epstein-Barr Virus, and Adenovirus Infections After Allogeneic Hematopoietic Stem-Cell Transplantation. J Clin Oncol. 2017 Nov 01; 35(31):3547-3557.
    View in: PubMed
    Score: 0.006
  19. Vaccination Targeting Native Receptors to Enhance the Function and Proliferation of Chimeric Antigen Receptor (CAR)-Modified T Cells. Clin Cancer Res. 2017 Jul 15; 23(14):3499-3509.
    View in: PubMed
    Score: 0.005
  20. General and Virus-Specific Immune Cell Reconstitution after Double Cord Blood Transplantation. Biol Blood Marrow Transplant. 2015 Jul; 21(7):1284-90.
    View in: PubMed
    Score: 0.005
  21. Gene therapy for rhesus monkeys heterozygous for LDL receptor deficiency by balloon catheter hepatic delivery of helper-dependent adenoviral vector. Gene Ther. 2015 Jan; 22(1):87-95.
    View in: PubMed
    Score: 0.005
  22. Long-term outcome after haploidentical stem cell transplant and infusion of T cells expressing the inducible caspase 9 safety transgene. Blood. 2014 Jun 19; 123(25):3895-905.
    View in: PubMed
    Score: 0.004
  23. Human papillomavirus type 16 E6/E7-specific cytotoxic T lymphocytes for adoptive immunotherapy of HPV-associated malignancies. J Immunother. 2013 Jan; 36(1):66-76.
    View in: PubMed
    Score: 0.004
  24. Oncolytic immunotherapy of advanced solid tumors with a CD40L-expressing replicating adenovirus: assessment of safety and immunologic responses in patients. Cancer Res. 2012 Apr 01; 72(7):1621-31.
    View in: PubMed
    Score: 0.004
  25. Generation of polyclonal CMV-specific T cells for the adoptive immunotherapy of glioblastoma. J Immunother. 2012 Feb-Mar; 35(2):159-68.
    View in: PubMed
    Score: 0.004
  26. Complete responses of relapsed lymphoma following genetic modification of tumor-antigen presenting cells and T-lymphocyte transfer. Blood. 2007 Oct 15; 110(8):2838-45.
    View in: PubMed
    Score: 0.003
  27. Adoptive immunotherapy for posttransplantation viral infections. Biol Blood Marrow Transplant. 2004 Mar; 10(3):143-55.
    View in: PubMed
    Score: 0.002
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.